Mainstay Medical provides company update and publishes 2018 full year results

News
- 18/04/2019

Dublin, Ireland: 18 April 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth operated by Euronext Dublin (MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, today provides a company update and announces the publication of its 2018 Full Year results and Annual Report.

  • ReActiv8-B study results received; pre-PMA submission meeting with FDA expected during the second quarter;
  • European commercialization continues to advance;
  • Cash on hand of US$ 15.5 million at 31 December 2018.

More info on Mainstay Medical’s website.